24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Open Access
- 1 November 2017
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 32 (6), 1025-1036
- https://doi.org/10.3904/kjim.2016.094
Abstract
Fimasartan is an angiotensin type 1 receptor blocker (ARB) which has comparable efficacy and tolerability with other ARBs. The aim of this study was to evaluate 24-hour blood pressure (BP) lowering efficacy and the tolerability of the low dose fimasartan compared with valsartan in patients with mild to moderate hypertension. This study was a phase II, prospective, multicenter, randomized, double-blind, parallel-grouped trial. A total of 75 hypertensive patients, whose mean ambulatory BP monitoring values were ≥ 135/85 mmHg, were randomized to either fimasartan 30 mg or valsartan 80 mg daily. The primary efficacy endpoint was the change in the mean 24-hour systolic BP (SBP) values from the baseline and at the week 8. Secondary endpoints included the change in the mean 24-hour diastolic BP values, the daytime and the nighttime mean BP values at week 8, the trough-to-peak (T/P) ratio and the smoothness index. At week 8, the mean 24-hour SBP values significantly decreased in both groups; –10.5 ± 11.9 mmHg (p < 0.0001) in the fimasartan group and –5.5 ± 11.6 mmHg (p = 0.0307) in the valsartan group. The difference between two groups was 4.3 ± 2.9 mmHg but there was no statistical significance (p = 0.1392). The global T/P ratio in the fimasartan 30 mg groups were 0.48 and 0.40 in the valsartan 80 mg group, respectively (p = 0.3411). The most frequent adverse events (AEs) were acute pharyngitis and there were no cases of severe AEs. In mild-to-moderate hypertensive patients, low dose (30 mg) fimasartan showed comparable 24-hour BP lowering efficacy compared with valsartan (80 mg). There was no difference in tolerability between two groups.Keywords
Funding Information
- Boryung Pharmaceutical
This publication has 38 references indexed in Scilit:
- Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study)American Journal of Cardiovascular Drugs, 2013
- Angiotensin Receptor Blockers: Pharmacology, Efficacy, and SafetyThe Journal of Clinical Hypertension, 2011
- Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy VolunteersJournal of Cardiovascular Pharmacology, 2011
- Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteersInt. Journal of Clinical Pharmacology and Therapeutics, 2011
- Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertensionEmergencias, 2008
- Rethinking the “Diseases of Affluence” Paradigm: Global Patterns of Nutritional Risks in Relation to Economic DevelopmentPLoS Medicine, 2005
- Angiotensin II Receptor BlockadeHypertension, 2003
- Interaction of ACE inhibitors and AT1-receptor blockers on maximum blood pressure response in spontaneous hypertensive ratsJournal of the Renin-Angiotensin-Aldosterone System, 2002
- Determining the Trough-to-Peak Ratio in Parallel-Group TrialsHypertension, 1997
- The Trough-to-Peak Ratio as an Instrument to Evaluate Antihypertensive DrugsHypertension, 1995